BMS-599626 is primarily investigated for its potential in cancer therapy, particularly as an inhibitor of specific kinases involved in tumor growth and progression. It targets HER1 and HER2 receptors, which are often overexpressed in various cancers, including breast, lung, and gastric cancers. By inhibiting these receptors, BMS-599626 disrupts signaling pathways that promote cancer cell proliferation and survival. This makes it a candidate for targeted therapy in patients with HER1/HER2-positive malignancies. Research focuses on its efficacy in preclinical models and its potential use in combination with other anticancer agents to enhance therapeutic outcomes. Its role in overcoming resistance to existing treatments is also under exploration.